Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Center to Use 454 Sequencing, NimbleGen Arrays in Disease Studies

NEW YORK (GenomeWeb News) – The Oxford Biomedical Research Centre will install several 454 GS FLX sequencing instruments and will use NimbleGen arrays to conduct genome-wide studies focused on finding links between human diseases and genetic mutations, 454 and NimbleGen parent company Roche said Thursday.
 
OxBRC is a partnership between Oxford Radcliffe Hospitals NHS Trust and the University of Oxford.
 
Oxford will use the NimbleGen arrays as a preparative tool for sequencing and genome-wide studies of samples with clinical documentation for selected diseases in three areas.
 
The researchers will sequence several genes for private familial mutations, they will conduct mutation screening in a large number of genes using both the 454 and NimbleGen technologies, and they will seek to identify genes and regions with genomic imbalances using the NimbleGen CGH Arrays.
 
Financial terms of the agreement were not released.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.